Status:
NOT_YET_RECRUITING
Reduction of Remifentanil-related Complications
Lead Sponsor:
Seoul National University Hospital
Conditions:
Anesthesia
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor sid...
Eligibility Criteria
Inclusion
- 18-70 year old
- ASA class 1-3 scheduled for elective surgery
Exclusion
- history of neurologic or mental disorder
- uncontrolled pulmonary or cardiovascular disease
- history of adverse reactions to opioids
- history of drug abuse
Key Trial Info
Start Date :
November 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01003028
Start Date
November 1 2024
End Date
December 1 2026
Last Update
December 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744